All Posts
  • Press Releases
1 min read

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

On this page

Share

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease company developing Type 1 regulatory T (Tr1) cell therapies, today announced two oral presentations at the American Society of Gene and Cell Therapy Annual Meeting 2026, May 11-15, 2026, in Boston.

Related Articles

Explore posts connected to this topic

View Resources

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and...

  • Interviews

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

First clinical data from Phase 1 dose-escalation study in patients

  • Press Releases

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos

In a clinical first, Tr1X Bio showed immune reconstitution and

  • Interviews

First clinical data from Phase 1 dose-escalation study in patients

  • Press Releases

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos